The Swedish
Drug Development Pipeline
& overview of companies with R&D activities in Sweden
Dec. 2013
Sara Gunnerås, Senior Manager Science & IP, SwedenBIO
SwedenBIO CEO Summit 2013, AstraZenaca Mölndal
Om uppdraget och rapporten
 Ta fram en rapport som kan användas för att synliggöra svensk FoU inom
läkemedelsektorn, både nationellt och internationellt.
 Verktyg för att visualisera industrins situation samt behov av stöd.
 Studien har gjorts årligen sedan 2006
 Kartlägga pågående läkemedelsprojekt bland svenska FoU företag.
 Nytt: Kartläggning av företagen med läkemedelsprojekt
 Rapporten sammanställs av SwedenBIO med finansiellt stöd från VINNOVA och
Business Sweden.
 AstraZeneca presenteras separat
The Swedish Drug Development Pipeline 2013
2
Pipeline & Companies
81 projects in phase I-III
67 unique molecules (small & large)
101 companies with R&D activity in Sweden
49 companies with phase I-III projects
The Swedish Drug Development Pipeline 2013
3
81 projects in clinical trials & 49 companies
100
No
81
76
75
50
25
74
73
65
67
63
49
46
24
34
30
33
38
42
35
0
2006
2007
2008
No of projects
The Swedish Drug Development Pipeline 2013
2009
2010
2011
2012
2013
No of companies
4
Projects by Phase including previous years
50
No of projects
47
40
30
20
20
14
10
0
Phase I
2006
2007
Phase II
2008
The Swedish Drug Development Pipeline 2013
2009
2010
Phase III
2011
2012
2013
5
Projects by Phase including previous years
50
No of projects
47
40
37
30
19 20
20
13 14
10
0
Phase I
2006
2007
Phase II
2008
The Swedish Drug Development Pipeline 2013
2009
2010
Phase III
2011
2012
2013
6
2012 - 2013
14
1
new molecules (not previously reported).
8
projects were reported as put on hold or outlicensed.
7
projects entered next phase.
phase 3 project was filed for registration during 2012.
The Swedish Drug Development Pipeline 2013
7
Therapeutic Areas
Cancer
Infection
CNS
Gastro-Intestinal
Diabetic/Metabolism
Pain
Inflammation
Endocrinology
Obstetrics
Cardiovascular
Dermatology
Other
0
The Swedish Drug Development Pipeline 2013
5
10
15
20
No of projects
25
8
Small and Large Molecules
50
No of projects
small molecules
large molecules
40
36
31
30
20
10
0
2006
2007
2008
The Swedish Drug Development Pipeline 2013
2009
2010
2011
2012
2013
9
Choice of Country for Clinical Trial, by Phase
No of projects
50
Abroad
40
Sweden & Abroad
30
Sweden
20
10
0
Phase I
Result only from questionnaire, 85% response
Phase II
Phase III
10
AstraZeneca, Global Drug Development Pipeline 2012
50
No of projects
47
40
30
29
25
19
20
14
11
10
0
AstraZeneca Pipeline
phase I
Source: AstraZeneca annual report 2012
Swedish Drug Development Pipeline
phase II
phase III
11
Products 2006 - 2012
Abstral - Cancer pain treatment, Orexo
Edluar - Insomnia treatment, Orexo
Emtrix/Nalox - Discolored and damaged nails, Moberg Derma
Episil - Pain for cancer patients suffering from oral mucositis, Camurus
Kaprolac - Anti-dandruff Shampoo, Moberg Derma
Plenadren - Treatment of adrenal insufficiency, DuoCort Pharma
Rapinyl - Cancer pain treatment, Orexo
Xerclear - Cold sore treatment, Medivir
Zonnic - Nicotine chewing gum, mouth spray, pouch and lozenge, Niconovum
Products reported via questionnaire 2006 - 2012
12
101 Companies with R&D activities in Sweden
Umeå, 5%
Stockholm/
Uppsala, 62%
Göteborg, 13%
Malmö/Lund, 20%
The Swedish Drug Development Pipeline 2013
13
R&D companies - size and employees
Micro (0-10 FTE)
Small (11-50 FTE)
Midsize (51-250 FTE)
Large (+250 FTE)
2% 2%
7% 2%
7%
12%
79%
101 companies
Source: www.allabolag.se. Information from 2012
89%
8256 employees
14
Top 10 Largest Companies by No of FTE
30%
Approx.
of pipeline projects
Source: www.allabolag.se. Information from 2012
15
Top 10 Largest Companies by Turnover
30%
Approx.
of pipeline projects
Source: www.allabolag.se. Information from 2012
16
Companies with R&D Activities in Sweden (Dec. 2012)
A1M Pharma
BioCrine
Glucox Biotech
Neuronova
Red Glead Discovery
Active Biotech
BioInvent International
Hansa Medical
Neurosearch Sweden
Redoxis
AcuCort
Camurus
Helicure
NeuroVive Pharmaceutical
Respiratorius
Acure Pharma
Cantargia
Hyron BioMedical
Strongbone
Adenovir Pharma
Cardoz
Immun System I.M.S.
Northern Light
Pharmaceuticals
Affibody
Akinion Pharmaceuticals
Albireo
Alligator Bioscience
Alzacure
Alzinova
Anamar
Apodemus
Aprea
AstraZeneca
Athera Biotechnologies
Axcentua Pharmaceuticals
Cebix
Chemilia
ChronTech Pharma
ClanoTech
Cortendo
Creative Antibiotics Sweden
DermaGen
Dextech Medical
Diamyd Medical
Dilafor
Dilaforette
Duecom Plus-A
Immunicum
InDex Pharmaceuticals
Isifer AB
Isofol Medical
Kancera
Karo Bio
KDev Exploratory
KDev Oncology
LIDDS
Lipidor
Lipigon Pharmaceuticals
Lipopeptide
Axelar
Edio HealthCare
Medivir
Betagenon
Eurocine Vaccines
Metakalinin
Bioarctic Neuroscience
Glactone Pharma
Moberg Derma
BioChromix Pharma
GliGene
Molecules of Man
The Swedish Drug Development Pipeline 2013
NovaSaid
Oasmia Pharmaceutical
Omnio Healer Umeå
Oncopeptides
Oncorena
Orexo
OxThera
Pep-Tonic Medical
Pergamum
Pharmalink
Pharmalundensis
Pharmanest
Scandinavian Biopharma
Swedish Orphan Biovitrum
Synphora
TikoMed
Toleranzia
Umecrine Cognition
Umecrine Mood
Velit Biologics
Vicore Pharma
WilsonTherapeutics
Vivolux
WntResearch
XImmune
PledPharma
Premacure
2012-12-31
Premune
Recopharma
17
Tack till alla som varit med och bidragit till rapporten!
sara.gunneras@swedenbio.com
Current and previous pipeline reports may be downloaded from: www.swedenbio.com/rapporter